TechNavio: Patent Expiries Will Pave the Way for the Generic Drugs Market in Japan
The Generic Drugs Market in Japan is expected to grow at a CAGR of 8.16% from 2014–2019, says research firm TechNavio.
According to the latest report by TechNavio, the patents of many first-generation approved biopharmaceuticals are set to expire within the forecast period, which will lead to intense competition from generic drugs.
However, due to the economic crisis, major companies in the market have allocated minimal funds for the R&D of innovative drugs, which has hindered the development of new drugs and paved the way for the generic drugs market.
“Pharmaceutical companies developing generic drugs have enormous opportunities to capitalise on the market at this point in time,” says Faisal Ghaus, Vice President of TechNavio.
The new TechNavio report also emphasises an increasing number of mergers and acquisitions, which will help vendors grow and expand their business. For a global company to enter the generic drugs market in Japan, it is important to form a partnership with a local manufacturer.
“In 2014, Teva acquired Taiyo Pharmaceutical, obtaining Taiyo Pharmaceutical’s portfolio of over 550 products. The company also gained access to Taiyo Pharmaceutical’s strong R&D team and local regulatory expertise,” says Ghaus.
Key Information Covered in the Report:
• Market segmentation, size and forecast through 2019
• Market Growth Drivers:
• Expiry of Patents
• For a full detailed list, view the report.
• Market Challenges:
• Intense Competition among Vendors
• For a full detailed list, view the report.
• Market Trends:
• Increase in M&A
• For a full detailed list, view the report.
• Key Vendors:
• Meiji Seika Pharma Co. Ltd.
• Nichi-Iko Pharmaceutical Co. Ltd.
• Nipro Pharma Corp.
• Sawai Pharmaceuticals Co. Ltd.
• Other Prominent Vendors:
• Actavis
• Daiichi Sankyo
• Daito Pharmaceutical
• Eisai
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance